Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions

a research study.

Anna Mária Tokés, J. Kulka, S. Paku, Agnes Szik, Csilla Páska, Pál Kaposi Novák, László Szilák, András Kiss, Krisztina Bögi, Z. Schaff

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions. METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases. RESULTS: CLDNs were rarely observed exclusively at tight junction structures. CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours). CLDN3 was present in 49 of the 56 sections and CLDN4 was present in all 56 tissue sections. However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia. CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene. CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue. CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis. The loss of CLDN4 expression in areas of apocrine metaplasia and in the majority of grade 1 invasive carcinomas also suggests a particular role for this protein in mammary glandular cell differentiation and carcinogenesis.

Original languageEnglish
JournalBreast Cancer Research
Volume7
Issue number2
Publication statusPublished - 2005

Fingerprint

Claudin-3
Claudin-1
Breast
Metaplasia
Messenger RNA
Research
Neoplasms
Breast Neoplasms
Proteins
Ductal Carcinoma
Carcinoma, Intraductal, Noninfiltrating
Tight Junctions
Real-Time Polymerase Chain Reaction
Cell Differentiation
Carcinogenesis
Down-Regulation
Epithelial Cells
Immunohistochemistry
Cell Membrane
Neoplasm Metastasis

Cite this

Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions : a research study. / Tokés, Anna Mária; Kulka, J.; Paku, S.; Szik, Agnes; Páska, Csilla; Novák, Pál Kaposi; Szilák, László; Kiss, András; Bögi, Krisztina; Schaff, Z.

In: Breast Cancer Research, Vol. 7, No. 2, 2005.

Research output: Contribution to journalArticle

Tokés, Anna Mária ; Kulka, J. ; Paku, S. ; Szik, Agnes ; Páska, Csilla ; Novák, Pál Kaposi ; Szilák, László ; Kiss, András ; Bögi, Krisztina ; Schaff, Z. / Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions : a research study. In: Breast Cancer Research. 2005 ; Vol. 7, No. 2.
@article{e6b53c6319474ccc875cde73649f9e78,
title = "Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.",
abstract = "INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions. METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases. RESULTS: CLDNs were rarely observed exclusively at tight junction structures. CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours). CLDN3 was present in 49 of the 56 sections and CLDN4 was present in all 56 tissue sections. However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia. CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene. CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue. CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis. The loss of CLDN4 expression in areas of apocrine metaplasia and in the majority of grade 1 invasive carcinomas also suggests a particular role for this protein in mammary glandular cell differentiation and carcinogenesis.",
author = "Tok{\'e}s, {Anna M{\'a}ria} and J. Kulka and S. Paku and Agnes Szik and Csilla P{\'a}ska and Nov{\'a}k, {P{\'a}l Kaposi} and L{\'a}szl{\'o} Szil{\'a}k and Andr{\'a}s Kiss and Krisztina B{\"o}gi and Z. Schaff",
year = "2005",
language = "English",
volume = "7",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions

T2 - a research study.

AU - Tokés, Anna Mária

AU - Kulka, J.

AU - Paku, S.

AU - Szik, Agnes

AU - Páska, Csilla

AU - Novák, Pál Kaposi

AU - Szilák, László

AU - Kiss, András

AU - Bögi, Krisztina

AU - Schaff, Z.

PY - 2005

Y1 - 2005

N2 - INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions. METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases. RESULTS: CLDNs were rarely observed exclusively at tight junction structures. CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours). CLDN3 was present in 49 of the 56 sections and CLDN4 was present in all 56 tissue sections. However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia. CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene. CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue. CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis. The loss of CLDN4 expression in areas of apocrine metaplasia and in the majority of grade 1 invasive carcinomas also suggests a particular role for this protein in mammary glandular cell differentiation and carcinogenesis.

AB - INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions. METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases. RESULTS: CLDNs were rarely observed exclusively at tight junction structures. CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours). CLDN3 was present in 49 of the 56 sections and CLDN4 was present in all 56 tissue sections. However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia. CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene. CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue. CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis. The loss of CLDN4 expression in areas of apocrine metaplasia and in the majority of grade 1 invasive carcinomas also suggests a particular role for this protein in mammary glandular cell differentiation and carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=18444417781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444417781&partnerID=8YFLogxK

M3 - Article

VL - 7

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 2

ER -